bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its new molecular biology affiliate, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the FilmArray® Gastrointestinal (GI) Panel1.
First-Quarter 2014 Business Review
Alexandre Mérieux Assumes Role of bioMérieux CEO
Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic plan, a new organization is being deployed.
bioMérieux Educates Future Microbiologists at the Triangle SciTech Expo
bioMérieux participated at the Triangle SciTech Expo by creating a fun and educational exhibit exposing youth to the microbiology field at the North Carolina Museum of Natural Sciences in Raleigh, NC.
bioMérieux 2013 Financial Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met yesterday and approved the consolidated financial statements for the year ended December 31, 2013.
bioMérieux Strengthens its Clostridium difficile Offer with the Launch of VIDAS® C. difficile GDH
VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase
BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel
BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.
bioMérieux's THxID®-BRAF Test for Detection of 2 BRAF Mutations V600E and V600K in Late-Stage Metastatic Melanoma Adopted by Clarient, a GE Healthcare Company
bioMérieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMérieux‘s molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient.
Business Review for the Year Ended December 31, 2013
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2013.
bioMérieux Finalizes Acquisition of the U.S. Company BioFire, Specialized in Molecular Biology
With this acquisition, bioMérieux consolidates its position as a major player in infectious disease diagnostics and strengthens its presence in the United States.